AI Article Synopsis
- Omori et al. discuss a case where a patient has liver metastases from two cancers: a primary mesenteric neuroendocrine tumor and rectal cancer.
- There is a possibility that the primary mesenteric tumor was actually a misidentified metastasis from an ileal neuroendocrine tumor, which is quite rare in Japan.
- The authors aim to clarify the characteristics of ileal neuroendocrine tumors and how they commonly present as mesenteric masses, drawing from the details of the reported case.
Article Abstract
Omori et al. reported a case of multiple liver metastases originating from synchronous double cancer of "primary mesenteric neuroendocrine tumor" and rectal cancer. However, the "primary mesenteric neuroendocrine tumor" might be a misrecognition of mesenteric metastasis from ileal neuroendocrine tumor. Ileal neuroendocrine tumor is extremely rare in Japan. Herein, we aim to describe the characteristics of ileal neuroendocrine tumor and mesenteric mass as its common manifestation in reference to their reported case.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246261 | PMC |
| http://dx.doi.org/10.1186/s40792-020-00875-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of dosimetry and clinical variables in treatments of neuroendocrine tumours with [Lu]Lu-DOTA-TATE.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
December 2024
Department of Nuclear Medicine, Gurutzeta-Cruces University Hospital/Biocruces Health Research Institute, Barakaldo, Spain.
Purpose: The main objectives were to study differences between the first and the fourth cycle in dosimetry variables in patients treated for neuroendocrine tumours with four cycles of [Lu]Lu-DOTA-TATE, as well as to look for absorbed dose-effect correlations aiming to help individualise and optimise this therapy for future patients.
Material And Methods: SPECT/CT based dosimetry of tumour lesions and kidneys was performed in the first and the fourth cycles of the [Lu]Lu-DOTA-TATE treatments for 17 patients from 2020 to 2023. Clinical variables of interest were collected in order to look for correlations with some dosimetry variables.
Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center.
World J Gastrointest Oncol
December 2024
Department of Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.
Background: Numerous studies have indicated that the temozolomide and capecitabine regimen (TEMCAP) exhibits a certain level of efficacy in treating advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, published data from Peru are limited. We hypothesize that this regimen could be a viable therapeutic option for advanced GEP-NET in the Peruvian population.
View Article and Find Full Text PDFUtility of F18-FDG PET/CT in the Evaluation of Pituitary Uptake.
World J Nucl Med
December 2024
Department of Nuclear Medicine, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
Pituitary adenoma is the most common disease that affects the gland and may be classified as functional/nonsecretory tumors. Inflammatory/infective causes may also affect the pituitary gland. The 18F-fluorodeoxyglucose positron emission tomography/computed tomography (F18-FDG PET/CT) may have an incremental value in assessing these lesions and in determining their clinical significance.
View Article and Find Full Text PDFMultifaceted modeling of small intestinal neuroendocrine tumors.
Endocr Oncol
January 2024
Neuroendocrine Cancer Therapy Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Small intestinal neuroendocrine tumors, siNETs, are a group of rare cancers that arise from neuroendocrine cells in the lining of the jejunum and ileum, which are either classified as tumors, siNETs, or small intestinal neuroendocrine carcinomas, siNECs. Current treatment strategies for low-grade tumors include surgical resection, peptide radionucleotide receptor therapy, and somatostatin analogues, while high-grade and recurrent tumors may receive cytotoxic chemotherapy. These limited treatment options are linked to the lack of representative models that can both reflect the biology of the tumor and are amenable to mid-to-high throughput experimentation.
View Article and Find Full Text PDFSerum and urinary 5-hydroxyindolacetic acid, serotonin, chromogranin A, and NT-proBNP for the detection of carcinoid heart disease.
Eur J Endocrinol
November 2024
Service de Biochimie et biologie moléculaire, Hospices Civils de Lyon, Bron 69500, France.
Objective: The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).
Design: An explorative ancillary study of the French CrusoeNET cohort.
Methods: Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS, and/or elevation of urinary 5-HIAA (u5HIAA) twice greater than the upper limit of normal.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!